Shockwave Medical, Inc. announced the global commercial availability of the Shockwave M5+ peripheral IVL catheter after receiving both CE Mark and U.S. Food and Drug Administration clearance. The Shockwave M5+ catheter, which has been in limited launch until March 31, 2022, is specifically designed to decrease IVL treatment time, provide alternative access options, and expand IVL therapy to patients with larger vessel sizes. Shockwave M5+ incorporates valued customer feedback to improve IVL efficiency in tackling complex calcified lesions, including quicker cycle time that delivers two pulses per second, an increased catheter length of 135 centimeters, and a new, larger 8.0 millimeter size.

The catheter is specifically designed to treat otherwise difficult-to-treat calcified lesions in the peripheral arterial system of the lower extremities, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. Shockwave M5+ is now commercially available in Europe and the United States.